Prima BioMed Ltd, a world leader in cancer immunotherapies, will visit the NASDAQ MarketSite in Times Square to celebrate its listing on The NASDAQ Stock Market. Prima BioMed Ltd. begins trading on NASDAQ today, April 16, 2012.
Prima's listing on NASDAQ comes at a significant point in the development timeline for CVac(TM) ovarian cancer vaccine. The timing should offer U.S, investors an opportunity to share in this growth phase of the Company.
In honor of the occasion, Martin Rogers, CEO will ring the Opening Bell.
Where:
NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio
When:
Monday, April 16, 2012 -- 9:15 a.m. to 9:30 a.m. ET
Contact:
Ian Bangs
+61 9276 1250
Ian.bangs@primabiomed.com.au
NASDAQ MarketSite:
Jen Knapp
(212) 401-8916
Jennifer.knapp@nasdaqomx.com
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/#!/NASDAQ.
For news tweets, please visit NASDAQ Twitter page at:
http://twitter.com/nasdaqomx
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Prima BioMed Ltd:
Prima BioMed is an ASX and NASDAQ listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology.
Prima's lead product is the CVacTM ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialisation in the United States, Australia, Europe, and globally.
The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.